Annual Report 2021
Department of Pharmacy
Toshikatsu Kawasaki, Yasuhiko Ichida, Reiko Matsui, Masahito Yonemura, Daisuke Kano, Naoko Kumazawa, Shinya Suzuki, Nobuo Mochizuki, Kenji Kawasumi, Misaki Takeno, Shinichi Masuda, Takahiro Akita, Ayumi Komuro, Chihiro Nakada, Yoshihiro Iwamoto, Sayaka Nakajima, Nobue Sato, Yoshiyuki Sano, Akiko Abe, Yui Suzuki, Masaki Tanaka, Kanako Mamishin, Takashi Igarashi, Tsuyoshi Uemoto, Wataru Suenaga, Hidetaka Suzuki, Yumiko Seto, Ken Demachi, Kensuke Mayumi, Asumi Kaneko, Kazuki Sugisaki, Yurie Saotome, Junko Tauchi, Kaho Miura, Manami Harada, Koki Morishita, Atsushi Kawanobe, Kaede Baba
Introduction
The main objectives of the Department of Pharmacy are: (1) To promote clinical studies to create new evidence-based data; (2) To provide chemotherapy based on the most updated evidence-based data; and (3) To pursue patient-centered pharmaceutical care.
Our residents’ training program started in 2006. In 2021, seven residents joined our department. Presently, we have a total of 17 residents. In addition, our department accepted eight trainees from other institutions for our oncology pharmacist training programs in 2021. In 2021, we educated three pharmacy students.
The Department of Pharmacy provides various important services: controlling inventory, dispensing medications, and preparing i.v. solutions for chemotherapy, which include the aseptic mixing of antineoplastic agents, collecting and providing drug information, managing therapeutic drug monitoring, checking treatment regimens for each patient’s chemotherapy, and providing pharmaceutical management and counseling.
Our department reviews the drugs taken by patients before and during their hospitalization. For inpatient care, our department assigns pharmacists to provide medication counseling and drug information for healthcare providers and patients, to pursue effective pharmaceutical care. In outpatient care, our department provides a pharmacy outpatient service in which pharmacists check patients for adverse reactions and doses of antineoplastic agents, especially in the case of oral anticancer medications. We then assess the necessity of supportive care medications and suggest them to physicians. The pharmacy outpatient service also reviews the drugs taken by all patients to assess the optimal time for them to stop their anticoagulants before their surgery or stop taking metformin before examinations with iodinated contrast material. Pharmacists are on duty at the Outpatient Chemotherapy Center as dedicated staff members. The pharmacists provide a Chemotherapy Hotline Service, which is a direct line for our outpatients who have any problems concerning their chemotherapy treatment. In the Outpatient Chemotherapy Center, pharmacists are always available to provide drug information for healthcare providers and patients. We also manage investigational drugs.
Research activities
We have presented oral sessions and poster sessions 11 times at national and international academic conferences. Ten scientific papers were accepted for publication.
List of papers published in 2021
Journal
1. Okunaka M, Kotani D, Demachi K, Fujiwara H, Sakashita S, Yoshino T, Fujita T, Kojima T. Significance of chemotherapy-free interval and tumor regression grade in patients with recurrent esophageal squamous cell carcinoma receiving chemotherapy with fluorouracil and platinum after esophagectomy following preoperative chemotherapy. Esophagus: official journal of the Japan Esophageal Society, 19:240-249, 2022
2. Nomura H, Tsuji D, Ueno S, Kojima T, Fujii S, Yano T, Daiko H, Demachi K, Itoh K, Kawasaki T. Relevance of pharmacogenetic polymorphisms with response to docetaxel, cisplatin, and 5-fluorouracil chemotherapy in esophageal cancer. Investigational new drugs, 40:420-429, 2022
3. Tsushima T, Sato N, Guo YM, Uchiyama S, Nakamura H, Nagata A, Song-Gi C, Yamauchi N, Minami Y, Yuda J. Combination therapy with low doses of ponatinib and steroids in elderly and frail patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Annals of hematology, 2022
4. Tsuno T, Fujimiya T, Kawaguchi T, Yanaizumi R, Kojima K, Miyasato A, Azuma K, Saeki T, Mawatari H, Igarashi T, Miura T, Ogura H, Kondo J, Tanoue T, Hamada H, Oyama Y, Kotani A, Yamaguchi T, Hakamata H. Psychological barriers to the use of opioid analgesics for treating pain in patients with advanced recurrent cancer (BAROC): protocol for a multicentre cohort study. BMJ open, 12:e054914, 2022
5. Tabata R, Sato N, Yamauchi N, Guo YM, Nakamura H, Nagata A, Song-Gi C, Minami Y, Yuda J. Cytomegalovirus reactivation in patients with multiple myeloma administered daratumumab-combination regimens. Annals of hematology, 101:465-467, 2022
6. Iwaki M, Kessoku T, Kanamori T, Abe K, Takeno N, Kawahara R, Fujimoto T, Igarashi T, Kumakura Y, Suzuki N, Kamiya K, Suzuki N, Tagami K, Saeki T, Mawatari H, Sakurai H, Higashibata T, Hirohashi T, Nakajima A, Ichikawa Y, Ishiki H. Tapentadol Safety and Patient Characteristics Associated with Treatment Discontinuation in Cancer Therapy: A Retrospective Multicentre Study in Japan. Pain and therapy, 10:1635-1648, 2021
7. Mamishin K, Naito Y, Nomura S, Ogawa G, Niguma K, Baba K, Sakaeda S, Nakajima H, Kusuhara S, Funasaka C, Nakao T, Fukasawa Y, Kondoh C, Harano K, Kogawa T, Matsubara N, Hosono A, Kawasaki T, Mukohara T. Comparison of Treatment Completion Rate Between Conventional and Dose-dense Doxorubicin and Cyclophosphamide (AC) Followed by a Taxane in Patients With Breast Cancer: A Propensity Score-matched Analysis. Anticancer research, 41:6217-6224, 2021
8. Miura K, Sano Y, Niho S, Kawasumi K, Mochizuki N, Yoh K, Matsumoto S, Zenke Y, Ikeda T, Nosaki K, Kirita K, Udagawa H, Goto K, Kawasaki T, Hanada K. Impact of concomitant medication on clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: A retrospective study. Thoracic cancer, 12:1983-1994, 2021
9. Suzuki H, Mitsunaga S, Ikeda M, Aoyama T, Yoshizawa K, Yoshimatsu H, Kawai N, Masuda M, Miura T, Ochiai A. Clinical and Tumor Characteristics of Patients with High Serum Levels of Growth Differentiation Factor 15 in Advanced Pancreatic Cancer. Cancers, 13:2021
10. Okunaka M, Kano D, Matsui R, Kawasaki T, Uesawa Y. Evaluation of the Expression Profile of Irinotecan-Induced Diarrhea in Patients with Colorectal Cancer. Pharmaceuticals (Basel, Switzerland), 14:2021
11. Kawasumi K, Kawano Y, Kujirai A, Mano Y, Matsui R, Maeda-Minami A, Yamamoto Y, Negishi K, Shimada S, Yamaguchi M, Nagata M, Aoyama T. Risk Factors Associated With Unplanned Acute Care in Outpatient Chemotherapy With Oral Anticancer Drugs as Monotherapy or Combination Therapy With Injectable Anticancer Drugs. Anticancer research, 41:5827-5834, 2021
12. Okunaka M, Kano D, Matsui R, Kawasaki T, Uesawa Y. Comprehensive Analysis of Chemotherapeutic Agents That Induce Infectious Neutropenia. Pharmaceuticals (Basel, Switzerland), 14:2021